Publikationsserver der Universitätsbibliothek Marburg
Titel:Salivary Aldosterone, Central and Peripheral Mineralocorticoid Receptor Function and Their Impact on the Course of Depression
Autor:Braunisch, Matthias Christoph
Weitere Beteiligte: Murck, Harald (PD Dr. med.)
Veröffentlicht:2017
URI:https://archiv.ub.uni-marburg.de/diss/z2017/0304
DOI: https://doi.org/10.17192/z2017.0304
URN: urn:nbn:de:hebis:04-z2017-03048
DDC:610 Medizin
Titel (trans.):Der Einfluss von Speichelaldosteron sowie der zentralen und peripheren Mineralokortikoidrezeptor-Funktion auf den Verlauf einer Depression
Publikationsdatum:2017-12-14
Lizenz:https://creativecommons.org/licenses/by-nc-nd/4.0/

Dokument

Schlagwörter:
Cortisol, depressive disorder, therapy refractoriness, salt appetite, therapierefraktäre Depression, Magnesium, Biomarker, Aldosteron, Herzfrequenzvariabilität, mineralocorticoid receptor, Salzappetit, Mineralokortikoidrezeptor, Depression, systolic blood press, Depression, Aldosterone, magnesium, sodium, Herzfrequenzv, Natrium, Tiefschlaf, cortisol, systolischer Blutdruck

Summary:
Background: Aldosterone and mineralocorticoid receptor (MR) function appear to play a role in depression. Central and peripheral biomarker parameters of MR function at baseline, their early (change within two weeks) and late (change within six weeks) plasticity were examined with regard to their relationship to clinical treatment outcome after six weeks in patients with acute major depression. Methods: Twenty-four patients with major depression were examined three times during six weeks. Aldosterone and cortisol salvia samples were taken at 7:00 am before patients got out of bed. Easy to use e-devices were used to measure markers of central MR function, i.e. slow wave sleep (SWS) and heart rate variability (HRV). A newly developed scale determined salt taste intensity (STI) and salt pleasantness (SP) of a 0.9% salt solution. In addition, systolic blood pressure (SBP) and plasma electrolytes (Mg2+, Na+, K+) were determined as markers of peripheral MR activity. The relationship between the levels of these biomarkers at baseline, their early and late plasticity and the relative change in clinical outcome parameters (Hamilton Depression Rating Scale with 6 and 21 items, QIDS-SR-16 and BDI) after six weeks of treatment was investigated. Results: By trend a higher baseline aldosterone to cortisol ratio (aldo/cort) (p < 0.1) and lower baseline SBP (p < 0.05) predicted poor outcome, independent of gender. Only in male patients lower baseline SP, lower SWS and higher HRV predicted beneficial outcome (p < 0.05). Likewise, in male patients low baseline Na+ appeared to be by trend predictive for a poor outcome (p = 0.050). Independent of gender an early cortisol reduction (p < 0.05) did predict clinical improvement, whereas by trend an early SWS increase was associated with better outcome (p < 0.1). Only in female patients an early Na+/K+ ratio increase appeared to be related to a better outcome (p < 0.05). By trend only in male patients a late HRV reduction was associated with beneficial outcome (p < 0.1). Conclusion: Correlates of higher baseline central MR activation were associated with poorer clinical improvement, particularly in men. This contrasted with a lower sensitivity of peripheral MR function at baseline in more refractory patients. As one potential mechanism to consider, Na+ loss on the basis of dysfunctional peripheral MR function and additional environmental factors may trigger increased aldosterone secretion and consequently lead to a less favorable outcome. Results for the parameter plasticity were heterogeneous. In the course of depression markers of increasing central as well as peripheral MR activation were found to be related to a favorable outcome. These makers were: decreasing cortisol (independent of aldosterone), increasing SWS, decreasing HRV and increasing Na+ plasma concentrations. Of note gender differences may exist in terms of MR function. This study showcases the usefulness of biological markers, which can be obtained at bedside, to achieve individualized medicine in therapy refractory depression.

Bibliographie / References

  1. MacFadyen, R.J., Barr, C.S., Struthers, A.D., 1997. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35, 30-34.
  2. Geerling, J.C., Loewy, A.D., 2009. Aldosterone in the brain. Am. J. Physiol. Renal Physiol. 297, F559-576.
  3. Charloux, A., Gronfier, C., Lonsdorfer-Wolf, E., Piquard, F., Brandenberger, G., 1999. Aldosterone release during the sleep-wake cycle in humans. Am. J. Physiol. 276, E43-49.
  4. Gerling, I.C., Sun, Y., Ahokas, R.A., Wodi, L.A., Bhattacharya, S.K., Warrington, K.J., Postlethwaite, A.E., Weber, K.T., 2003. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am. J. Physiol. Heart Circ. Physiol. 285, H813-821.
  5. Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56- 62.
  6. Jacka, F.N., Overland, S., Stewart, R., Tell, G.S., Bjelland, I., Mykletun, A., 2009. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry 43, 45-52.
  7. Howren, M.B., Lamkin, D.M., Suls, J., 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71, 171-186.
  8. Born, J., Steinbach, D., Dodt, C., Fehm, H.L., 1997. Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. J. Clin. Endocrinol. Metab. 82, 1106-1110.
  9. Francis, J., Weiss, R.M., Johnson, A.K., Felder, R.B., 2003. Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R328-335.
  10. Francis, J., Weiss, R.M., Wei, S.G., Johnson, A.K., Beltz, T.G., Zimmerman, K., Felder, R.B., 2001. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am. J. Physiol. Heart Circ. Physiol. 281, H2241-2251.
  11. Casper, R.C., Kocsis, J., Dysken, M., Stokes, P., Croughan, J., Maas, J., 1988. Cortisol measures in primary major depressive disorder with hypersomnia or appetite increase. J Affect Disord 15, 131-140.
  12. Gonzalez, M.B., Snyderman, T.B., Colket, J.T., Arias, R.M., Jiang, J.W., O'Connor, C.M., Krishnan, K.R., 1996. Depression in patients with coronary artery disease. Depression 4, 57- 62.
  13. Horton, R., Biglieri, E.G., 1962. Effect of aldosterone on the metabolism of magnesium. J. Clin. Endocrinol. Metab. 22, 1187-1192.
  14. Barr, C.S., Lang, C.C., Hanson, J., Arnott, M., Kennedy, N., Struthers, A.D., 1995. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 76, 1259-1265.
  15. Bondy, B., Baghai, T.C., Zill, P., Schule, C., Eser, D., Deiml, T., Zwanzger, P., Ella, R., Rupprecht, R., 2005. Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1094-1099.
  16. Born, J., DeKloet, E.R., Wenz, H., Kern, W., Fehm, H.L., 1991. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am. J. Physiol. 260, E183-188.
  17. Krystal, J.H., Sanacora, G., Blumberg, H., Anand, A., Charney, D.S., Marek, G., Epperson, C.N., Goddard, A., Mason, G.F., 2002. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 7 Suppl 1, S71-80.
  18. Murck, H., Fava, M., Alpert, J., Nierenberg, A.A., Mischoulon, D., Otto, M.W., Zajecka, J., Mannel, M., Rosenbaum, J.F., 2005. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int. J. Neuropsychopharmacol. 8, 215-221.
  19. Kemp, A.H., Quintana, D.S., Gray, M.A., Felmingham, K.L., Brown, K., Gatt, J.M., 2010. Impact of depression and antidepressant treatment on heart rate variability: a review and metaanalysis. Biol. Psychiatry 67, 1067-1074.
  20. Emanuele, E., Geroldi, D., Minoretti, P., Coen, E., Politi, P., 2005. Increased plasma aldosterone in patients with clinical depression. Arch. Med. Res. 36, 544-548.
  21. Eby III, G.A., Eby, K.L., 2010. Magnesium for treatment-resistant depression: A review and hypothesis. Medical hypotheses 74, 649-660.
  22. Carney, R.M., Rich, M.W., Tevelde, A., Saini, J., Clark, K., Jaffe, A.S., 1987. Major depressive disorder in coronary artery disease. Am. J. Cardiol. 60, 1273-1275.
  23. Makatsori, A., Duncko, R., Moncek, F., Loder, I., Katina, S., Jezova, D., 2004. Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug lamotrigine. Neuroendocrinology 79, 34- 42.
  24. Grippo, A.J., Francis, J., Beltz, T.G., Felder, R.B., Johnson, A.K., 2005. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. Physiol. Behav. 84, 697-706.
  25. Kang, Y.-M., Zhang, Z.-H., Johnson, R.F., Yu, Y., Beltz, T., Johnson, A.K., Weiss, R.M., Felder, R.B., 2006. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ. Res. 99, 758-766.
  26. Eller, T., Vasar, V., Shlik, J., Maron, E., 2008. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 445-450.
  27. Bech, P., 2006. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci 8, 207-215.
  28. Kennedy, N., Abbott, R., Paykel, E.S., 2003. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. Psychol Med 33, 827-838.
  29. Keller, M.B., Klein, D.N., Hirschfeld, R.M., Kocsis, J.H., McCullough, J.P., Miller, I., First, M.B., Holzer, C.P., 3rd, Keitner, G.I., Marin, D.B., 1995. Results of the DSM-IV mood disorders field trial. Am J Psychiatry 152, 843-849.
  30. Duprez, D.A., 2006. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J. Hypertens. 24, 983-991.
  31. Fluharty, S.J., Epstein, A.N., 1983. Sodium appetite elicited by intracerebroventricular infusion of angiotensin II in the rat: II. Synergistic interaction with systemic mineralocorticoids. Behav. Neurosci. 97, 746-758.
  32. Hlavacova, N., Wes, P.D., Ondrejcakova, M., Flynn, M.E., Poundstone, P.K., Babic, S., Murck, H., Jezova, D., 2011. Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 1-19.
  33. Charlton, J.A., Armstrong, D.G., 1989. The effect of an intravenous infusion of aldosterone upon magnesium metabolism in the sheep. Q J Exp Physiol 74, 329-337.
  34. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., Wang, P.S., 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105.
  35. Lecrubier, Y., Bech, P., 2007. The Ham D(6) is more homogenous and as sensitive as the Ham D(17). Eur. Psychiatry 22, 252-255.
  36. Bech, P., Stage, K.B., Larsen, J.K., Vestergaard, P., Gram, L.F., 2012. The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine. Journal of affective disorders.
  37. Holsboer, F., 1999. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33, 181-214.
  38. Murck, H., Held, K., Ziegenbein, M., Künzel, H., Koch, K., Steiger, A., 2003. The reninangiotensin-aldosterone system in patients with depression compared to controls--a sleep endocrine study. BMC Psychiatry 3, 15.
  39. Gelenberg, A.J., Kocsis, J.H., McCullough, J.P., Ninan, P.T., Thase, M.E., 2006. The State of Knowledge of Chronic Depression. Prim Care Companion J Clin Psychiatry 8, 60-65.

* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten
© UB Marburg 1997 - 2024 Universitätsbibliothek Marburg